Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology
F
Biotech is Zen Rated F and is the 140th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Exchange
Industry
Zen Rating
Market Cap
Price
1d %
EBITDA
P/E
D/E
Country
DD Score
AUPH
AURINIA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$1.11B$8.18-0.61%$65.88M28.21x0.44
Canada
EXEL
EXELIXIS INC
NASDAQ
Biotechnology
$11.34B$41.59-0.45%$894.63M18.48x0.33
United States
CPRX
CATALYST PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.87B$23.53-3.13%$296.55M14.26x0.14
United States
RIGL
RIGEL PHARMACEUTICALS INC
NASDAQ
Biotechnology
$366.74M$20.52-3.66%$48.45M9.77x8.48
United States
HALO
HALOZYME THERAPEUTICS INC
NASDAQ
Biotechnology
$6.65B$53.98-1.03%$704.60M14.02x3.56
United States
PBYI
PUMA BIOTECHNOLOGY INC
NASDAQ
Biotechnology
$166.29M$3.35-5.90%$54.66M4.35x1.02
United States
BCRX
BIOCRYST PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.17B$10.37-0.29%$47.59M-39.88x-2.06
United States
PTCT
PTC THERAPEUTICS INC
NASDAQ
Biotechnology
$4.06B$51.260.55%$846.90M6.78x-15.30
United States
CRMD
CORMEDIX INC
NASDAQ
Biotechnology
$987.53M$14.56-2.02%$17.67M56.00x0.30
United States
BMRN
BIOMARIN PHARMACEUTICAL INC
NASDAQ
Biotechnology
$10.78B$56.22-1.85%$777.43M20.44x0.23
United States
INCY
INCYTE CORP
NASDAQ
Biotechnology
$13.11B$67.75-2.12%$406.83M233.62x0.57
United States
NAGE
NIAGEN BIOSCIENCE INC
NASDAQ
Biotechnology
$1.07B$13.63-3.61%$16.04M75.72x0.47
United States
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
NASDAQ
Biotechnology
$1.89B$32.97-1.08%$237.95M12.35x0.47
United States
ZVRA
ZEVRA THERAPEUTICS INC
NASDAQ
Biotechnology
$499.23M$9.13-2.56%-$60.30M-4.76x3.21
United States
CSBR
CHAMPIONS ONCOLOGY INC
NASDAQ
Biotechnology
$105.91M$7.663.58%$8.10M16.30x4.60
United States
ONC
BEONE MEDICINES LTD
NASDAQ
Biotechnology
$29.13B$269.63-2.50%-$126.93M-929.76x0.67
Cayman Islands
AKBA
AKEBIA THERAPEUTICS INC
NASDAQ
Biotechnology
$934.98M$3.56-2.47%$10.87M-16.18x11.62
United States
THTX
THERATECHNOLOGIES INC
NASDAQ
Biotechnology
$114.03M$2.48-1.98%$11.53M-44.29x-3.31
Canada
ARWR
ARROWHEAD PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.17B$15.74-2.96%-$57.42M-11.57x1.30
United States
PLX
PROTALIX BIOTHERAPEUTICS INC
NYSEMKT
Biotechnology
$118.61M$1.49-3.25%$7.16M29.80x0.63
Israel
VCYT
VERACYTE INC
NASDAQ
Biotechnology
$2.07B$26.44-0.94%$63.03M61.49x0.10
United States
XOMA
XOMA ROYALTY CORP
NASDAQ
Biotechnology
$285.41M$23.85-3.05%$3.33M-21.68x1.51
United States
MDXG
MIMEDX GROUP INC
NASDAQ
Biotechnology
$892.12M$6.04-1.31%$63.32M22.37x0.33
United States
INVA
INNOVIVA INC
NASDAQ
Biotechnology
$1.36B$21.691.36%$14.61M-22.83x0.94
United States
MNKD
MANNKIND CORP
NASDAQ
Biotechnology
$1.13B$3.71-3.13%$82.59M37.10x-8.00
United States
HRTX
HERON THERAPEUTICS INC
NASDAQ
Biotechnology
$294.45M$1.93-3.98%-$2.95M-38.60x-9.29
United States
XLO
XILIO THERAPEUTICS INC
NASDAQ
Biotechnology
$34.28M$0.66-3.22%-$52.61M-0.81x8.69
United States
ZLAB
ZAI LAB LTD
NASDAQ
Biotechnology
$4.45B$41.00-4.72%-$227.62M-17.08x0.45
China
NVO
NOVO NORDISK A S
NYSE
Biotechnology
$356.44B$79.83-1.51%$23.12B22.37x2.53
Denmark
BDTX
BLACK DIAMOND THERAPEUTICS INC
NASDAQ
Biotechnology
$131.35M$2.31-4.94%$5.44M28.88x0.25
United States
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
NASDAQ
Biotechnology
$2.07B$28.302.06%-$1.55M-117.92x0.31
Bermuda
IMCR
IMMUNOCORE HOLDINGS PLC
NASDAQ
Biotechnology
$1.74B$34.68-2.67%$1.93M-80.65x1.72
United Kingdom
GMAB
GENMAB A
NASDAQ
Biotechnology
$15.11B$22.82-1.17%N/A13.17x0.24
Denmark
VIVS
VIVOSIM LABS INC
NASDAQ
Biotechnology
$4.19M$1.61-6.94%-$1.78M-0.95x0.40
United States
MIRM
MIRUM PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.46B$49.631.24%-$35.81M-30.83x1.96
United States
STOK
STOKE THERAPEUTICS INC
NASDAQ
Biotechnology
$629.50M$11.53-2.45%$42.86M13.56x0.16
United States
FENC
FENNEC PHARMACEUTICALS INC
NASDAQ
Biotechnology
$219.02M$7.93-4.69%-$11.14M-14.96x-8.89
United States
RPRX
ROYALTY PHARMA PLC
NASDAQ
Biotechnology
$19.59B$34.84-1.22%$1.34B14.11x0.80
United States
VRNA
VERONA PHARMA PLC
NASDAQ
Biotechnology
$7.85B$92.20-0.32%-$121.41M-46.10x1.32
United Kingdom
VXRT
VAXART INC
NASDAQ
Biotechnology
$160.21M$0.7030.73%-$48.89M-2.60x2.48
United States
TECH
BIO-TECHNE CORP
NASDAQ
Biotechnology
$7.92B$50.52-1.96%$289.57M60.87x0.31
United States
VRTX
VERTEX PHARMACEUTICALS INC
NASDAQ
Biotechnology
$116.96B$455.45-1.00%-$74.90M-119.23x0.39
United States
ALNY
ALNYLAM PHARMACEUTICALS INC
NASDAQ
Biotechnology
$40.16B$307.991.09%-$164.54M-147.36x35.50
United States
IMAB
I-MAB
NASDAQ
Biotechnology
$203.29M$2.49-3.49%N/A-21.65x0.05
China
UTHR
UNITED THERAPEUTICS CORP
NASDAQ
Biotechnology
$12.78B$283.35-0.98%$1.68B10.46x0.14
United States
ARGX
ARGENX SE
NASDAQ
Biotechnology
$35.11B$577.89-1.51%$114.32M38.19x0.13
Belgium
TGTX
TG THERAPEUTICS INC
NASDAQ
Biotechnology
$5.72B$36.01-3.64%$70.41M133.37x1.77
United States
ATRA
ATARA BIOTHERAPEUTICS INC
NASDAQ
Biotechnology
$52.58M$8.821.26%$7.38M-3.43x-2.13
United States
ARQT
ARCUTIS BIOTHERAPEUTICS INC
NASDAQ
Biotechnology
$1.60B$13.43-0.52%-$100.65M-13.04x1.41
United States
XERS
XERIS BIOPHARMA HOLDINGS INC
NASDAQ
Biotechnology
$696.67M$4.35-1.58%-$4.34M-14.50x-9.98
United States
NVAX
NOVAVAX INC
NASDAQ
Biotechnology
$1.12B$6.94-2.94%$554.90M2.29x-18.09
United States
TLX
TELIX PHARMACEUTICALS LTD
NASDAQ
Biotechnology
$5.39B$16.09-7.85%$58.49MN/A1.67
Australia
TBPH
THERAVANCE BIOPHARMA INC
NASDAQ
Biotechnology
$534.51M$10.690.75%-$39.82M-9.06x1.07
Cayman Islands
TARS
TARSUS PHARMACEUTICALS INC
NASDAQ
Biotechnology
$1.72B$40.89-0.15%-$93.78M-15.03x0.46
United States
ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ
Biotechnology
$3.63B$21.71-0.14%$278.16M15.73x0.48
United States
WHWK
WHITEHAWK THERAPEUTICS INC
NASDAQ
Biotechnology
$92.33M$1.96-3.92%$28.33M12.25x0.06
United States
GLUE
MONTE ROSA THERAPEUTICS INC
NASDAQ
Biotechnology
$302.01M$4.91-0.20%$17.73M61.38x0.43
United States
ZYME
ZYMEWORKS INC
NASDAQ
Biotechnology
$882.89M$12.67-3.28%-$94.99M-8.45x0.31
Canada
KROS
KEROS THERAPEUTICS INC
NASDAQ
Biotechnology
$550.75M$13.56-0.59%$17.92M-113.00x0.08
United States
CTMX
CYTOMX THERAPEUTICS INC
NASDAQ
Biotechnology
$221.71M$2.75-8.03%$47.70M5.61x2.93
United States
AGEN
AGENUS INC
NASDAQ
Biotechnology
$128.86M$4.70-2.49%-$76.47M-0.55x-1.53
United States
LGND
LIGAND PHARMACEUTICALS INC
NASDAQ
Biotechnology
$2.17B$112.50-1.70%-$119.89M-15.63x0.14
United States
FTRE
FORTREA HOLDINGS INC
NASDAQ
Biotechnology
$531.90M$5.91-5.74%-$577.60M-0.67x2.63
United States
CORT
CORCEPT THERAPEUTICS INC
NASDAQ
Biotechnology
$7.43B$70.06-1.57%$110.98M55.17x0.24
United States
SEER
SEER INC
NASDAQ
Biotechnology
$121.86M$2.07-2.82%-$79.33M-1.47x0.12
United States
KRYS
KRYSTAL BIOTECH INC
NASDAQ
Biotechnology
$3.96B$137.07-2.32%$144.76M31.73x0.09
United States
RGNX
REGENXBIO INC
NASDAQ
Biotechnology
$464.99M$9.27-9.12%-$122.44M-2.99x0.79
United States
TVRD
TVARDI THERAPEUTICS INC
NASDAQ
Biotechnology
$230.47M$24.62-5.71%-$35.47M-0.82x-5.82
United States
PVLA
PALVELLA THERAPEUTICS INC
NASDAQ
Biotechnology
$276.94M$25.05-5.19%-$15.17M-5.35x0.43
United States
IPSC
CENTURY THERAPEUTICS INC
NASDAQ
Biotechnology
$49.54M$0.58-4.17%-$8.40M-1.98x0.31
United States
TVTX
TRAVERE THERAPEUTICS INC
NASDAQ
Biotechnology
$1.29B$14.50-2.95%-$169.03M-5.20x15.72
United States
SEPN
SEPTERNA INC
NASDAQ
Biotechnology
$453.16M$10.17-2.31%N/AN/A0.08
United States
GYRE
GYRE THERAPEUTICS INC
NASDAQ
Biotechnology
$749.12M$7.99-0.99%$13.36M99.88x0.37
United States
MESO
MESOBLAST LTD
NASDAQ
Biotechnology
$1.36B$11.78-3.13%N/A-12.68x0.42
Australia
FHTX
FOGHORN THERAPEUTICS INC
NASDAQ
Biotechnology
$240.80M$4.32-4.85%-$71.61M-3.18x-5.20
United States
TSHA
TAYSHA GENE THERAPIES INC
NASDAQ
Biotechnology
$545.24M$2.54-4.15%-$84.24M-7.47x1.51
United States
ACIU
AC IMMUNE SA
NASDAQ
Biotechnology
$195.80M$1.95-5.80%-$60.62M-3.08x1.23
Switzerland
NTRB
NUTRIBAND INC
NASDAQ
Biotechnology
$79.75M$7.15-5.92%-$9.65M-7.94x0.21
United States
ACOG
ALPHA COGNITION INC
NASDAQ
Biotechnology
$149.79M$9.35-2.65%-$11.47M-7.19x0.19
Canada
MCRB
SERES THERAPEUTICS INC
NASDAQ
Biotechnology
$65.49M$7.50-6.13%$90.27M0.86x2.25
United States
MDGL
MADRIGAL PHARMACEUTICALS INC
NASDAQ
Biotechnology
$6.56B$295.57-0.55%-$376.50M-16.48x0.40
United States
ADMA
ADMA BIOLOGICS INC
NASDAQ
Biotechnology
$4.97B$20.81-3.66%$160.80M23.65x0.37
United States
AEON
AEON BIOPHARMA INC
NYSEMKT
Biotechnology
$10.30M$0.912.13%$169.21M0.00x-2.22
United States
KYMR
KYMERA THERAPEUTICS INC
NASDAQ
Biotechnology
$3.06B$46.96-0.70%-$232.67M-15.10x0.17
United States
ABVC
ABVC BIOPHARMA INC
NASDAQ
Biotechnology
$29.69M$1.77-4.32%-$1.24M-13.62x1.28
United States
GERN
GERON CORP
NASDAQ
Biotechnology
$961.75M$1.51-3.21%-$114.49M-7.19x1.10
United States
FOLD
AMICUS THERAPEUTICS INC
NASDAQ
Biotechnology
$1.86B$6.03-2.27%$53.63M-67.00x3.08
United States
FULC
FULCRUM THERAPEUTICS INC
NASDAQ
Biotechnology
$369.76M$6.851.03%$957.00k-685.00x0.06
United States
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
NASDAQ
Biotechnology
$1.57B$10.32-0.86%-$106.35M-10.86x1.68
United States
REGN
REGENERON PHARMACEUTICALS INC
NASDAQ
Biotechnology
$57.14B$529.241.42%$5.53B12.67x0.28
United States
ARVN
ARVINAS INC
NASDAQ
Biotechnology
$539.41M$7.39-2.38%-$39.80M-11.20x0.52
United States
CADL
CANDEL THERAPEUTICS INC
NASDAQ
Biotechnology
$257.03M$5.13-4.29%-$36.56M-3.92x0.28
United States
IMNM
IMMUNOME INC
NASDAQ
Biotechnology
$800.51M$9.20-6.03%-$202.55M-2.89x0.12
United States
SLS
SELLAS LIFE SCIENCES GROUP INC
NASDAQ
Biotechnology
$165.63M$1.660.61%-$26.56M-4.37x0.26
United States
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
NASDAQ
Biotechnology
$2.74B$31.51-1.59%-$32.47M-42.99x8.87
China
LEGN
LEGEND BIOTECH CORP
NASDAQ
Biotechnology
$6.78B$36.83-2.85%-$153.44M-30.69x0.59
United States
CNTA
CENTESSA PHARMACEUTICALS PLC
NASDAQ
Biotechnology
$1.65B$12.382.82%-$208.73M-6.59x0.37
United Kingdom
GOSS
GOSSAMER BIO INC
NASDAQ
Biotechnology
$281.85M$1.24-2.36%-$35.70M-5.39x-45.89
United States
ASND
ASCENDIS PHARMA A
NASDAQ
Biotechnology
$10.37B$170.80-0.07%-$194.68M-25.69x-6.59
Denmark
RARE
ULTRAGENYX PHARMACEUTICAL INC
NASDAQ
Biotechnology
$3.54B$37.49-4.58%-$511.44M-6.39x8.46
United States

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Jun 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Aurinia Pharmaceuticals (NASDAQ:AUPH)


Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #1 top biotech stock out of 653 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 62, which is 38 points higher than the biotech industry average of 24.

AUPH passed 20 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 52.9% over the past year, overperforming other biotech stocks by 129 percentage points.

2. Exelixis (NASDAQ:EXEL)


Exelixis (NASDAQ:EXEL) is the #2 top biotech stock out of 653 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Exelixis (NASDAQ:EXEL) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Exelixis (NASDAQ:EXEL) has a Due Diligence Score of 67, which is 43 points higher than the biotech industry average of 24.

EXEL passed 22 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock return 89.39% over the past year, overperforming other biotech stocks by 166 percentage points.

Exelixis has an average 1 year price target of $39.94, a downside of -3.97% from Exelixis's current stock price of $41.59.

Exelixis stock has a consensus Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Exelixis, 31.25% have issued a Strong Buy rating, 18.75% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Catalyst Pharmaceuticals (NASDAQ:CPRX)


Catalyst Pharmaceuticals (NASDAQ:CPRX) is the #3 top biotech stock out of 653 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Catalyst Pharmaceuticals (NASDAQ:CPRX) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: D, Financials: A, and AI: C.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a Due Diligence Score of 73, which is 49 points higher than the biotech industry average of 24.

CPRX passed 24 out of 33 due diligence checks and has strong fundamentals. Catalyst Pharmaceuticals has seen its stock return 53.49% over the past year, overperforming other biotech stocks by 130 percentage points.

Catalyst Pharmaceuticals has an average 1 year price target of $32.50, an upside of 38.12% from Catalyst Pharmaceuticals's current stock price of $23.53.

Catalyst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Catalyst Pharmaceuticals, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 6.58%, which is 5 percentage points higher than the biotech industry average of 1.63%.

Dominari Holdings's dividend payout ratio of -7.1% indicates that its high dividend yield might not be sustainable for the long-term.

2. Novo Nordisk (Ozempic) (NYSE:NVO)


Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.02%, which is the same as the biotech industry average of 1.63%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.2% indicates that its dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.87%, which is the same as the biotech industry average of 1.63%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 34.4% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.4% in the last day, and down -1.07% over the last week. Biorestorative Therapies was the among the top losers in the biotechnology industry, dropping -16% yesterday.

BioRestorative Therapies shares are trading lower. The company announced the presentation of promising preliminary blinded data from the first 36 subjects in its ongoing Phase 2 clinical trial of BRTX-100.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 0.9% in the past year. It has overperformed other stocks in the biotech industry by 77 percentage points.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 10.79% in the past year. It has overperformed other stocks in the biotech industry by 87 percentage points.

3. United Therapeutics (NASDAQ:UTHR)


United Therapeutics (NASDAQ:UTHR) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

United Therapeutics has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

United Therapeutics's stock has dropped -1.47% in the past year. It has overperformed other stocks in the biotech industry by 75 percentage points.

Are biotech stocks a good buy now?

53.31% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 99.94% over the next year.

2.39% of biotech stocks have a Zen Rating of A (Strong Buy), 4.56% of biotech stocks are rated B (Buy), 35.57% are rated C (Hold), 36.66% are rated D (Sell), and 20.82% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -108.97x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.